Shamburg News · 8-K filed Nov 2, 2026, 7:39 AM EST
CorMedix Reports Approximately $355 Million Cash, Reaffirms 2026 Revenue Guidance
CRMD · CorMedix Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
On November 2, 2026, CorMedix Therapeutics issued a business update reporting unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026. The company reaffirmed its August 2026 full-year 2026 total revenue guidance of between $325 million and $345 million. It also disclosed that CMS set a Q1 2027 post-TDAPA Add-on of $8.32 per dialysis session for DefenCath, and that it expects a conference call on November 12, 2026 to discuss full quarterly results.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001213900-26-114665.
Written from the filing by Shamburg Markets. Figures are as reported by the company.